Overview

Feasibility of Prophylactic Haldol to Prevent Delirium in Cancer Patients

Status:
Completed
Trial end date:
2013-10-01
Target enrollment:
Participant gender:
Summary
This research study proposes to conduct an open label, feasibility study administering prophylactic oral haldol to patients undergoing a hematopoietic stem cell transplant (HSCT). The study will address the following research aims: 1) To demonstrate the feasibility of enrolling HSCT patients in a prophylactic medication trial, 2) To determine the tolerability of oral haldol in HSCT patients and 2) To compare rates of delirium in HSCT patients who receive prophylactic haldol with an untreated historical control group.
Phase:
Phase 4
Details
Lead Sponsor:
Michelle Weckmann
Collaborator:
American Cancer Society, Inc.
Treatments:
Haloperidol
Haloperidol decanoate